Armistice Capital
GOSS icon

Armistice Capital’s Gossamer Bio GOSS Stock Holding History

Armistice Capital’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-51,950
Closed -$3.79M – 369
2023
Q4 		$3.79M Sell
51,950
-10,000
-16% -$591K 0.05% 133
2023
Q3 		$4.13M Buy
+61,950
New +$5.71M 0.06% 118

Other funds holding GOSS

NEA Management Company
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EcoR1 Capital
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Octagon Capital Advisors
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Palo Alto Investors
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Armistice Capital's GOSS Position: Q1 2024 in Review

Armistice Capital sold out of Gossamer Bio (GOSS) in Q1 2024, closing a stake of 51,950 shares — an estimated $3.79M sold.

Armistice Capital first reported a position in GOSS in Q3 2023 and held it in 2 quarters. The position peaked at $4.13M in Q3 2023. 108 funds tracked by Wall St. Rank hold GOSS as of Q1 2024.

  • Armistice Capital reported no remaining Gossamer Bio position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 51,950 Gossamer Bio shares in Q1 2024, an estimated $3.79M.
  • Armistice Capital first reported a position in Gossamer Bio in Q3 2023 and held it in 2 quarters.
  • Armistice Capital's Gossamer Bio position peaked at $4.13M in Q3 2023.
  • 108 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.